Pharmaxis Starts Exporting Its Cystic Fibrosis Drug to The USA Following FDA Approval

9th Feb 21

Release Date: 09/02/2021 8:45am

Pharmaceutical research company Pharmaxis Ltd (ASX: PXS) has announced it has exported the first shipment of its locally developed and manufactured drug Bronchitol®(mannitol) to the USA. The cystic fibrosis (CF) treatment was approved by the US Food and Drug Administration (FDA) on 30 October 2020. Following receipt of an initial payment of US$7 million (~A$10 million) from its exclusive US distributor Chiesi, Pharmaxis will now receive a further US$3 million (~A$4 million) milestone payment.

Read full media release - pdf

Categories: News and Media